About: Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset
Creator	Yuen, Kwok-Yung Zhou, Jie Qin, Chuan Gao, Hong Chu, Hin Yeung, Man-Lung Yao, Yanfeng Chen, Honglin Cai, Jian-Piao Jia, Lilong Bao, Linlin Xiao, Chong Deng, Wei Yu, Pin Chan, Fuk-Woo, Jasper Li, Fengdi
Source	Medline; PMC
abstract	Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe disease in human with an overall case-fatality rate of >35%. Effective antivirals are crucial for improving the clinical outcome of MERS. Although a number of repurposed drugs, convalescent-phase plasma, antiviral peptides, and neutralizing antibodies exhibit anti-MERS-CoV activity in vitro, most are not readily available or have not been evaluated in nonhuman primates. We assessed 3 repurposed drugs with potent in vitro anti-MERS-CoV activity (mycophenolate mofetil [MMF], lopinavir/ritonavir, and interferon-β1b) in common marmosets with severe disease resembling MERS in humans. The lopinavir/ritonavir-treated and interferon-β1b-treated animals had better outcome than the untreated animals, with improved clinical (mean clinical scores ↓50.9%–95.0% and ↓weight loss than the untreated animals), radiological (minimal pulmonary infiltrates), and pathological (mild bronchointerstitial pneumonia) findings, and lower mean viral loads in necropsied lung (↓0.59–1.06 log(10) copies/glyceraldehyde 3-phosphate dehydrogenase [GAPDH]; P < .050) and extrapulmonary (↓0.11–1.29 log(10) copies/GAPDH; P < .050 in kidney) tissues. In contrast, all MMF-treated animals developed severe and/or fatal disease with higher mean viral loads (↑0.15–0.54 log(10) copies/GAPDH) than the untreated animals. The mortality rate at 36 hours postinoculation was 67% (untreated and MMF-treated) versus 0–33% (lopinavir/ritonavir-treated and interferon-β1b-treated). Lopinavir/ritonavir and interferon-β1b alone or in combination should be evaluated in clinical trials. MMF alone may worsen MERS and should not be used.
has issue date	2015-12-15(xsd:dateTime)
bibo:doi	10.1093/infdis/jiv392
bibo:pmid	26198719
has license	no-cc
sha1sum (hex)	e305232d5d27febe713580b020ad5cfa9d47a4dc
schema:url	https://doi.org/10.1093/infdis/jiv392
resource representing a document's title	Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset
has PubMed Central identifier	PMC7107395
has PubMed identifier	26198719
schema:publication	J Infect Dis
resource representing a document's body	covid:e305232d5d27febe713580b020ad5cfa9d47a4dc#body_text
is schema:about of	named entity 'animals' named entity 'viral' named entity 'developed' named entity 'mild' named entity 'minimal' covid:arg/e305232d5d27febe713580b020ad5cfa9d47a4dc named entity 'animals' named entity 'The' named entity 'pathological' named entity 'severe' named entity 'MMF' named entity 'marmosets' named entity 'MMF' named entity 'GAPDH' named entity 'MERS' named entity 'disease' named entity 'animals' named entity 'glyceraldehyde 3-phosphate dehydrogenase' named entity 'disease' named entity 'evaluated' named entity 'MERS' named entity 'pneumonia' named entity 'Model' named entity 'Primate' named entity 'neutralizing antibodies' named entity 'mortality rate' named entity 'repurposed drugs' named entity 'interferon' named entity 'GAPDH' named entity 'clinical trials' named entity 'repurposed drugs' named entity 'GAPDH' named entity 'improving' named entity 'lungs' named entity 'clinical trials' named entity 'organ' named entity 'assay' named entity 'edema' named entity 'lopinavir' named entity 'lopinavir/ritonavir' named entity 'Pulmonary alveoli' named entity 'anesthesia' named entity 'DPP4' named entity 'inoculation' named entity 'parenteral' named entity 'intravenous' named entity 'fibrin' named entity 'ribavirin' named entity 'hpi' named entity 'Interferon' named entity 'rhesus macaques' named entity 'lymphocytes' named entity 'serum level' named entity 'MERS' named entity 'MERS' named entity 'interferon' named entity 'hemorrhage' named entity 'immunofluorescent' named entity 'synergistic' named entity 'viremia' named entity 'CXR' named entity 'GAPDH' named entity 'clinical trials' named entity 'hpi' named entity 'nucleocapsid protein'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software